Unfortunately, despite the well-accepted roles of fibrosis in cardiac dysfunction, no targeted antifibrotic drugs for the heart exist. Thus, it is crucial to understand the fundamental mechanisms that drive cardiac fibrosis so that novel approaches to thwart this pathogenic process can be discovered.
Resident fibroblasts in the heart are major contributors to cardiac fibrosis (6,7). In response to stress, these cells undergo a cell state transition to become activated fibroblasts, sometimes referred to as myofibroblasts, which produce high levels of ECM. (13) and Fan et al. (14) established that cardiomyocyte Hsp20 levels and phosphorylation at serine-16 were increased by b-adrenergic stimulation, which resulted in protection against apoptosis. Subsequently, they discovered that transgenic mice with cardiomyocytespecific expression of Hsp20 were protected from ischemia-reperfusion injury (15) . The protective effects of Hsp20 in the heart were corroborated by other groups using distinct cell-based and in vivo models of cardiac stress (16) . Furthermore, cell culture studies that used Hsp20 derivatives harboring a phosphomimetic or a non-phosphorylatable amino acid in place of serine-16, and S16D and S16A, respectively, implicated protein kinase A (PKA)À or protein kinase DÀmediated phosphorylation of this site as a beneficial signaling event in cardiomyocytes (16) .
Paradoxically, in the current study, Gardner et al.
(10) showed that cardiomyocyte-specific expression of Hsp20-S16D in mice led to systolic dysfunction and 100% mortality in <1 year. In contrast, there were no Science author instructions page. deleterious effects of transgene-mediated expression of non-phosphorylatable Hsp20-H16A in the heart. Hsp20-S16D transgenic mice exhibited significant interstitial fibrosis before evidence of myocyte apoptosis, which led the investigators to postulate that phospho-Hsp20 could be triggering reactive interstitial fibrosis through paracrine activation of resident fibroblasts. Consistent with this notion, exposure of cultured cardiac fibroblasts to medium from cultured cardiomyocytes ectopically expressing Hsp20-S16D, but not Hsp20-S16A, led to a modest increase in fibroblast activation markers. The investigators went on to show that Hsp20-S16D promotes production and secretion of interleukin-6 (IL-6), which has the capacity to stimulate cardiac fibro- associates with the actin cytoskeleton and transmits activating signals to nuclear transcription factors (TFs) that stimulate production of interleukin (IL)-6. IL-6, secreted from cardiomyocytes, functions in a paracrine manner to stimulate resident cardiac fibroblasts.
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Regulates Myocyte-to-Fibroblast Crosstalk that, counter to the conclusions of the current study, Hsp20 phosphorylation is cardioprotective (19, 20) .
Because of potential translational significance of Hsp20 phosphorylation, it will be critical to extend the findings of Gardner et al. (10) 
